Contract analysis

I. Executive Summary The purpose of this memorandum is to analyze Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") exposure to transfer pricing penalties under Internal Revenue Code ("IRC") § 6662(e) and to assess the strength of available defenses, with particular focus on the reasonable cause and contemporaneous documentation defenses set forth in IRC § 6662(e)(3)(B) and the implementing regulations at Tre

II. Statutory and Regulatory Framework This Section provides a comprehensive overview of the statutory and regulatory framework governing the imposition and defense of transfer pricing penalties. An understanding of this framework is essential to assessing PPC's penalty exposure and the strength of its available defenses. A. IRC § 6662(a) and (b)(3) — Accuracy-Related Penalty Generally IRC § 6662(a) imposes a penalty

III. Analysis of PPC's Contemporaneous Transfer Pricing Documentation A. Documentation Prepared by Crestfield & Associates LLP For each of TY 2017, 2018, 2019, and 2020, Crestfield & Associates LLP prepared contemporaneous transfer pricing documentation under IRC § 6662(e) penalty-protection standards. The documentation engagement was led by Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner),

IV. Reasonable Cause and Good Faith Defense — General Standards Even if the IRS were to contend that PPC's contemporaneous documentation does not fully satisfy the regulatory checklist, PPC retains the general reasonable cause and good faith defense under IRC § 6664(c). This defense is available independently of the contemporaneous documentation safe harbor and may provide an additional layer of protection against th

V. Case Law on Transfer Pricing Penalties and Reasonable Cause The case law on transfer pricing penalties under IRC § 6662(e) provides important guidance on the standards courts apply in evaluating the contemporaneous documentation defense and the reasonable cause defense. While each case turns on its own facts, several principles emerge from the decided cases that are instructive for PPC's penalty defense. A. Cases

VI. Application to PPC's Specific Positions This Section applies the statutory, regulatory, and case law framework discussed above to each of PPC's specific transfer pricing positions at issue in the examination. A. CSA Cost-Sharing Ratios PPC's cost-sharing ratios, under which PBI bore 38.2% (TY 2017), 39.6% (TY 2018), 41.1% (TY 2019), and 42.7% (TY 2020) of annual qualified R&D costs, are based on reasonably antici